nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—TLR4—esophageal cancer	0.693	0.894	CbGaD
Naloxone—ABCB1—esophageal cancer	0.0826	0.107	CbGaD
Naloxone—SLCO1A2—Methotrexate—esophageal cancer	0.0208	0.454	CbGbCtD
Naloxone—ALB—Methotrexate—esophageal cancer	0.0108	0.235	CbGbCtD
Naloxone—ABCB1—Cisplatin—esophageal cancer	0.00867	0.189	CbGbCtD
Naloxone—ABCB1—Methotrexate—esophageal cancer	0.00563	0.123	CbGbCtD
Naloxone—CREB1—exocrine gland—esophageal cancer	0.00456	0.157	CbGeAlD
Naloxone—CREB1—neck—esophageal cancer	0.00292	0.1	CbGeAlD
Naloxone—TLR4—lung—esophageal cancer	0.00286	0.0986	CbGeAlD
Naloxone—CREB1—epithelium—esophageal cancer	0.00198	0.0683	CbGeAlD
Naloxone—TLR4—lymph node—esophageal cancer	0.00196	0.0674	CbGeAlD
Naloxone—CREB1—bronchus—esophageal cancer	0.00195	0.0673	CbGeAlD
Naloxone—CREB1—smooth muscle tissue—esophageal cancer	0.00191	0.0658	CbGeAlD
Naloxone—CREB1—digestive system—esophageal cancer	0.00151	0.052	CbGeAlD
Naloxone—CREB1—lung—esophageal cancer	0.00126	0.0434	CbGeAlD
Naloxone—ESR1—neck—esophageal cancer	0.00115	0.0395	CbGeAlD
Naloxone—CREB1—lymph node—esophageal cancer	0.000863	0.0297	CbGeAlD
Naloxone—ESR1—epithelium—esophageal cancer	0.000781	0.0269	CbGeAlD
Naloxone—ESR1—smooth muscle tissue—esophageal cancer	0.000753	0.0259	CbGeAlD
Naloxone—SLCO1A2—digestive system—esophageal cancer	0.000701	0.0241	CbGeAlD
Naloxone—Shivering—Capecitabine—esophageal cancer	0.00065	0.0589	CcSEcCtD
Naloxone—Buprenorphine—CYP2A6—esophageal cancer	0.000604	0.339	CrCbGaD
Naloxone—ESR1—digestive system—esophageal cancer	0.000594	0.0205	CbGeAlD
Naloxone—SLCO1A2—lung—esophageal cancer	0.000585	0.0201	CbGeAlD
Naloxone—ESR1—lung—esophageal cancer	0.000496	0.0171	CbGeAlD
Naloxone—Hydromorphone—PTGS1—esophageal cancer	0.000456	0.256	CrCbGaD
Naloxone—Sneezing—Capecitabine—esophageal cancer	0.000437	0.0397	CcSEcCtD
Naloxone—Rhinorrhoea—Cisplatin—esophageal cancer	0.000405	0.0368	CcSEcCtD
Naloxone—ALB—lymph node—esophageal cancer	0.000398	0.0137	CbGeAlD
Naloxone—Encephalopathy—Capecitabine—esophageal cancer	0.000377	0.0342	CcSEcCtD
Naloxone—Pain—Carboplatin—esophageal cancer	0.000341	0.031	CcSEcCtD
Naloxone—ESR1—lymph node—esophageal cancer	0.00034	0.0117	CbGeAlD
Naloxone—CYP3A4—digestive system—esophageal cancer	0.000332	0.0114	CbGeAlD
Naloxone—Ventricular fibrillation—Capecitabine—esophageal cancer	0.000316	0.0287	CcSEcCtD
Naloxone—Body temperature increased—Carboplatin—esophageal cancer	0.000316	0.0286	CcSEcCtD
Naloxone—ABCB1—epithelium—esophageal cancer	0.000309	0.0106	CbGeAlD
Naloxone—Naltrexone—ABCB1—esophageal cancer	0.000306	0.172	CrCbGaD
Naloxone—Rhinorrhoea—Capecitabine—esophageal cancer	0.000299	0.0271	CcSEcCtD
Naloxone—Encephalopathy—Methotrexate—esophageal cancer	0.000281	0.0255	CcSEcCtD
Naloxone—ABCB1—trachea—esophageal cancer	0.000273	0.00939	CbGeAlD
Naloxone—Injection site reaction—Capecitabine—esophageal cancer	0.000241	0.0218	CcSEcCtD
Naloxone—ABCB1—digestive system—esophageal cancer	0.000235	0.00808	CbGeAlD
Naloxone—Irritability—Cisplatin—esophageal cancer	0.000227	0.0206	CcSEcCtD
Naloxone—Buprenorphine—ABCB1—esophageal cancer	0.000225	0.126	CrCbGaD
Naloxone—Nasopharyngitis—Cisplatin—esophageal cancer	0.000213	0.0193	CcSEcCtD
Naloxone—ABCB1—lung—esophageal cancer	0.000196	0.00675	CbGeAlD
Naloxone—Morphine—ABCB1—esophageal cancer	0.000188	0.106	CrCbGaD
Naloxone—Hot flush—Capecitabine—esophageal cancer	0.000188	0.017	CcSEcCtD
Naloxone—Menopausal symptoms—Capecitabine—esophageal cancer	0.000186	0.0169	CcSEcCtD
Naloxone—Irritability—Capecitabine—esophageal cancer	0.000168	0.0152	CcSEcCtD
Naloxone—Cardiac arrest—Capecitabine—esophageal cancer	0.000167	0.0152	CcSEcCtD
Naloxone—Coma—Methotrexate—esophageal cancer	0.000165	0.0149	CcSEcCtD
Naloxone—Pulmonary oedema—Methotrexate—esophageal cancer	0.00016	0.0145	CcSEcCtD
Naloxone—Nasopharyngitis—Capecitabine—esophageal cancer	0.000157	0.0142	CcSEcCtD
Naloxone—Cardiac disorder—Cisplatin—esophageal cancer	0.000153	0.0139	CcSEcCtD
Naloxone—Flushing—Cisplatin—esophageal cancer	0.000153	0.0139	CcSEcCtD
Naloxone—Mediastinal disorder—Cisplatin—esophageal cancer	0.000149	0.0135	CcSEcCtD
Naloxone—Depression—Capecitabine—esophageal cancer	0.000135	0.0122	CcSEcCtD
Naloxone—Tremor—Cisplatin—esophageal cancer	0.000134	0.0122	CcSEcCtD
Naloxone—ABCB1—lymph node—esophageal cancer	0.000134	0.00461	CbGeAlD
Naloxone—Irritability—Methotrexate—esophageal cancer	0.000125	0.0113	CcSEcCtD
Naloxone—Convulsion—Cisplatin—esophageal cancer	0.000124	0.0113	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000121	0.011	CcSEcCtD
Naloxone—Nervous system disorder—Cisplatin—esophageal cancer	0.000115	0.0104	CcSEcCtD
Naloxone—Tachycardia—Cisplatin—esophageal cancer	0.000114	0.0104	CcSEcCtD
Naloxone—Skin disorder—Cisplatin—esophageal cancer	0.000114	0.0103	CcSEcCtD
Naloxone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000113	0.0103	CcSEcCtD
Naloxone—Cardiac disorder—Capecitabine—esophageal cancer	0.000113	0.0102	CcSEcCtD
Naloxone—Flushing—Capecitabine—esophageal cancer	0.000113	0.0102	CcSEcCtD
Naloxone—Angiopathy—Capecitabine—esophageal cancer	0.00011	0.01	CcSEcCtD
Naloxone—Mediastinal disorder—Capecitabine—esophageal cancer	0.00011	0.00994	CcSEcCtD
Naloxone—Chills—Capecitabine—esophageal cancer	0.000109	0.00989	CcSEcCtD
Naloxone—Mental disorder—Capecitabine—esophageal cancer	0.000106	0.00966	CcSEcCtD
Naloxone—Paraesthesia—Cisplatin—esophageal cancer	0.000105	0.00954	CcSEcCtD
Naloxone—Dyspnoea—Cisplatin—esophageal cancer	0.000104	0.00947	CcSEcCtD
Naloxone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000101	0.00917	CcSEcCtD
Naloxone—Depression—Methotrexate—esophageal cancer	0.0001	0.00912	CcSEcCtD
Naloxone—Pain—Cisplatin—esophageal cancer	0.0001	0.00909	CcSEcCtD
Naloxone—Tremor—Capecitabine—esophageal cancer	9.91e-05	0.00899	CcSEcCtD
Naloxone—Sweating—Methotrexate—esophageal cancer	9.66e-05	0.00876	CcSEcCtD
Naloxone—Body temperature increased—Cisplatin—esophageal cancer	9.26e-05	0.0084	CcSEcCtD
Naloxone—Hypertension—Capecitabine—esophageal cancer	9.13e-05	0.00829	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	8.94e-05	0.00811	CcSEcCtD
Naloxone—Nervous system disorder—Capecitabine—esophageal cancer	8.47e-05	0.00768	CcSEcCtD
Naloxone—Tachycardia—Capecitabine—esophageal cancer	8.42e-05	0.00764	CcSEcCtD
Naloxone—Asthenia—Cisplatin—esophageal cancer	8.4e-05	0.00762	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—esophageal cancer	8.39e-05	0.00762	CcSEcCtD
Naloxone—Skin disorder—Capecitabine—esophageal cancer	8.38e-05	0.00761	CcSEcCtD
Naloxone—Hyperhidrosis—Capecitabine—esophageal cancer	8.35e-05	0.00757	CcSEcCtD
Naloxone—Angiopathy—Methotrexate—esophageal cancer	8.21e-05	0.00745	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—esophageal cancer	8.15e-05	0.0074	CcSEcCtD
Naloxone—Chills—Methotrexate—esophageal cancer	8.12e-05	0.00736	CcSEcCtD
Naloxone—Diarrhoea—Cisplatin—esophageal cancer	8.01e-05	0.00727	CcSEcCtD
Naloxone—Mental disorder—Methotrexate—esophageal cancer	7.92e-05	0.00719	CcSEcCtD
Naloxone—Paraesthesia—Capecitabine—esophageal cancer	7.75e-05	0.00703	CcSEcCtD
Naloxone—Dyspnoea—Capecitabine—esophageal cancer	7.7e-05	0.00698	CcSEcCtD
Naloxone—Gastrointestinal disorder—Capecitabine—esophageal cancer	7.45e-05	0.00676	CcSEcCtD
Naloxone—Vomiting—Cisplatin—esophageal cancer	7.45e-05	0.00676	CcSEcCtD
Naloxone—Pain—Capecitabine—esophageal cancer	7.38e-05	0.0067	CcSEcCtD
Naloxone—Nausea—Cisplatin—esophageal cancer	6.96e-05	0.00631	CcSEcCtD
Naloxone—Abdominal pain—Capecitabine—esophageal cancer	6.82e-05	0.00619	CcSEcCtD
Naloxone—Body temperature increased—Capecitabine—esophageal cancer	6.82e-05	0.00619	CcSEcCtD
Naloxone—Convulsion—Methotrexate—esophageal cancer	6.82e-05	0.00619	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	6.66e-05	0.00604	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—esophageal cancer	6.3e-05	0.00572	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—esophageal cancer	6.24e-05	0.00566	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—esophageal cancer	6.21e-05	0.00564	CcSEcCtD
Naloxone—Asthenia—Capecitabine—esophageal cancer	6.19e-05	0.00562	CcSEcCtD
Naloxone—Diarrhoea—Capecitabine—esophageal cancer	5.91e-05	0.00536	CcSEcCtD
Naloxone—Paraesthesia—Methotrexate—esophageal cancer	5.77e-05	0.00524	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—esophageal cancer	5.73e-05	0.0052	CcSEcCtD
Naloxone—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.55e-05	0.00503	CcSEcCtD
Naloxone—Pain—Methotrexate—esophageal cancer	5.5e-05	0.00499	CcSEcCtD
Naloxone—Vomiting—Capecitabine—esophageal cancer	5.49e-05	0.00498	CcSEcCtD
Naloxone—Nausea—Capecitabine—esophageal cancer	5.13e-05	0.00465	CcSEcCtD
Naloxone—Abdominal pain—Methotrexate—esophageal cancer	5.08e-05	0.00461	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—esophageal cancer	5.08e-05	0.00461	CcSEcCtD
Naloxone—Asthenia—Methotrexate—esophageal cancer	4.61e-05	0.00418	CcSEcCtD
Naloxone—Diarrhoea—Methotrexate—esophageal cancer	4.4e-05	0.00399	CcSEcCtD
Naloxone—Vomiting—Methotrexate—esophageal cancer	4.09e-05	0.00371	CcSEcCtD
Naloxone—Nausea—Methotrexate—esophageal cancer	3.82e-05	0.00346	CcSEcCtD
Naloxone—CREB1—Adaptive Immune System—EGFR—esophageal cancer	1.39e-05	0.000102	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL2—esophageal cancer	1.39e-05	0.000101	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOTCH3—esophageal cancer	1.38e-05	0.000101	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GHRL—esophageal cancer	1.38e-05	0.000101	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALOX15—esophageal cancer	1.38e-05	0.000101	CbGpPWpGaD
Naloxone—ALB—Metabolism—ALOX15—esophageal cancer	1.37e-05	0.0001	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ABCB1—esophageal cancer	1.36e-05	9.96e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FBXW7—esophageal cancer	1.36e-05	9.92e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—CREBBP—esophageal cancer	1.34e-05	9.81e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ADH1B—esophageal cancer	1.32e-05	9.69e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTO1—esophageal cancer	1.31e-05	9.62e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TPI1—esophageal cancer	1.31e-05	9.62e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTO1—esophageal cancer	1.31e-05	9.56e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—TPI1—esophageal cancer	1.31e-05	9.56e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFBR2—esophageal cancer	1.3e-05	9.5e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.3e-05	9.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PSME1—esophageal cancer	1.3e-05	9.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PSME2—esophageal cancer	1.3e-05	9.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ANXA1—esophageal cancer	1.29e-05	9.43e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.29e-05	9.42e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.29e-05	9.42e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TYMP—esophageal cancer	1.27e-05	9.26e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALDOB—esophageal cancer	1.26e-05	9.22e-05	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—PIK3CA—esophageal cancer	1.26e-05	9.2e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SST—esophageal cancer	1.25e-05	9.18e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ALDOB—esophageal cancer	1.25e-05	9.17e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—BCL2—esophageal cancer	1.25e-05	9.16e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.24e-05	9.09e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOTCH2—esophageal cancer	1.24e-05	9.05e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.23e-05	9.01e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SMAD4—esophageal cancer	1.23e-05	8.99e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GHRL—esophageal cancer	1.22e-05	8.94e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOTCH3—esophageal cancer	1.22e-05	8.94e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS2—esophageal cancer	1.22e-05	8.93e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—ERBB2—esophageal cancer	1.22e-05	8.9e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.22e-05	8.89e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GAPDH—esophageal cancer	1.21e-05	8.87e-05	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—PIK3CA—esophageal cancer	1.21e-05	8.83e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GAPDH—esophageal cancer	1.21e-05	8.82e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FBXW7—esophageal cancer	1.2e-05	8.8e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CRABP1—esophageal cancer	1.2e-05	8.79e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS3—esophageal cancer	1.2e-05	8.79e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALOX15—esophageal cancer	1.2e-05	8.78e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CRABP1—esophageal cancer	1.2e-05	8.74e-05	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—MYC—esophageal cancer	1.17e-05	8.53e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HIF1A—esophageal cancer	1.15e-05	8.41e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HIF1A—esophageal cancer	1.15e-05	8.39e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TPI1—esophageal cancer	1.15e-05	8.38e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTO1—esophageal cancer	1.15e-05	8.38e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GNG7—esophageal cancer	1.14e-05	8.37e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GNG7—esophageal cancer	1.14e-05	8.32e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—ERBB2—esophageal cancer	1.12e-05	8.22e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KDR—esophageal cancer	1.1e-05	8.05e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PTGS2—esophageal cancer	1.1e-05	8.04e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALDOB—esophageal cancer	1.1e-05	8.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFBR2—esophageal cancer	1.1e-05	8.03e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOTCH2—esophageal cancer	1.1e-05	8.02e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KDR—esophageal cancer	1.1e-05	8.02e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—CREBBP—esophageal cancer	1.1e-05	8.02e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.09e-05	8.01e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CA1—esophageal cancer	1.09e-05	8.01e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.07e-05	7.84e-05	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	1.07e-05	7.84e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ALDH2—esophageal cancer	1.07e-05	7.79e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GAPDH—esophageal cancer	1.06e-05	7.73e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.05e-05	7.72e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CRABP1—esophageal cancer	1.05e-05	7.66e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—NOTCH1—esophageal cancer	1.04e-05	7.64e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—CDKN1A—esophageal cancer	1.04e-05	7.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SMAD4—esophageal cancer	1.04e-05	7.6e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NOTCH1—esophageal cancer	1.04e-05	7.58e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NOTCH1—esophageal cancer	1.03e-05	7.56e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.03e-05	7.53e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.02e-05	7.47e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.02e-05	7.46e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTT1—esophageal cancer	1.01e-05	7.41e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.01e-05	7.37e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HIF1A—esophageal cancer	1.01e-05	7.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1e-05	7.34e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP2A6—esophageal cancer	1e-05	7.33e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CA2—esophageal cancer	1e-05	7.33e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.98e-06	7.3e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GNG7—esophageal cancer	9.96e-06	7.29e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EP300—esophageal cancer	9.9e-06	7.24e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS3—esophageal cancer	9.81e-06	7.18e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFBR2—esophageal cancer	9.73e-06	7.12e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KDR—esophageal cancer	9.61e-06	7.03e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—CDKN1A—esophageal cancer	9.6e-06	7.02e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ENO1—esophageal cancer	9.55e-06	6.99e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS1—esophageal cancer	9.55e-06	6.99e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ENO1—esophageal cancer	9.5e-06	6.95e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS1—esophageal cancer	9.5e-06	6.95e-05	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	9.49e-06	6.94e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—CREBBP—esophageal cancer	9.46e-06	6.92e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PSME2—esophageal cancer	9.41e-06	6.88e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PSME1—esophageal cancer	9.41e-06	6.88e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CREBBP—esophageal cancer	9.39e-06	6.87e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CREBBP—esophageal cancer	9.36e-06	6.85e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PSME2—esophageal cancer	9.36e-06	6.85e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PSME1—esophageal cancer	9.36e-06	6.85e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALDH2—esophageal cancer	9.33e-06	6.83e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLCE1—esophageal cancer	9.31e-06	6.81e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ADH7—esophageal cancer	9.31e-06	6.81e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EGFR—esophageal cancer	9.23e-06	6.75e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SMAD4—esophageal cancer	9.21e-06	6.74e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EGFR—esophageal cancer	9.2e-06	6.73e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EP300—esophageal cancer	9.14e-06	6.68e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CREBBP—esophageal cancer	9.1e-06	6.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NOTCH1—esophageal cancer	9.06e-06	6.63e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTT1—esophageal cancer	8.88e-06	6.5e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.79e-06	6.43e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP2A6—esophageal cancer	8.78e-06	6.42e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HIF1A—esophageal cancer	8.5e-06	6.22e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—esophageal cancer	8.43e-06	6.17e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NOS3—esophageal cancer	8.41e-06	6.15e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NOS3—esophageal cancer	8.38e-06	6.13e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ENO1—esophageal cancer	8.32e-06	6.09e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS1—esophageal cancer	8.32e-06	6.09e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.31e-06	6.08e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.22e-06	6.01e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CREBBP—esophageal cancer	8.21e-06	6.01e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PSME2—esophageal cancer	8.2e-06	6e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PSME1—esophageal cancer	8.2e-06	6e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.17e-06	5.98e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.16e-06	5.97e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NOS3—esophageal cancer	8.14e-06	5.96e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KDR—esophageal cancer	8.13e-06	5.94e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP1B1—esophageal cancer	8.12e-06	5.94e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP1B1—esophageal cancer	8.07e-06	5.91e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—esophageal cancer	8.07e-06	5.9e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PIK3CA—esophageal cancer	8.01e-06	5.86e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PIK3CA—esophageal cancer	7.99e-06	5.84e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MYC—esophageal cancer	7.96e-06	5.82e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB2—esophageal cancer	7.87e-06	5.76e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB2—esophageal cancer	7.84e-06	5.74e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMP—esophageal cancer	7.8e-06	5.71e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—esophageal cancer	7.79e-06	5.7e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PIK3CA—esophageal cancer	7.71e-06	5.64e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOTCH1—esophageal cancer	7.65e-06	5.6e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP19A1—esophageal cancer	7.63e-06	5.59e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP19A1—esophageal cancer	7.59e-06	5.55e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	7.59e-06	5.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HIF1A—esophageal cancer	7.53e-06	5.51e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—EP300—esophageal cancer	7.46e-06	5.46e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—esophageal cancer	7.45e-06	5.45e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.4e-06	5.41e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NOS3—esophageal cancer	7.35e-06	5.38e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIK3CA—esophageal cancer	7.32e-06	5.36e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KDR—esophageal cancer	7.2e-06	5.27e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1B1—esophageal cancer	7.07e-06	5.18e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.05e-06	5.16e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TPI1—esophageal cancer	7.05e-06	5.16e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PIK3CA—esophageal cancer	7e-06	5.12e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HMOX1—esophageal cancer	6.97e-06	5.1e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—esophageal cancer	6.95e-06	5.09e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CREBBP—esophageal cancer	6.94e-06	5.08e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—esophageal cancer	6.93e-06	5.07e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—HMOX1—esophageal cancer	6.93e-06	5.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—esophageal cancer	6.88e-06	5.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.83e-06	5e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—esophageal cancer	6.82e-06	4.99e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.8e-06	4.97e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOTCH1—esophageal cancer	6.79e-06	4.97e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.76e-06	4.95e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PIK3CA—esophageal cancer	6.76e-06	4.94e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1A—esophageal cancer	6.72e-06	4.92e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1A—esophageal cancer	6.7e-06	4.9e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ABCB1—esophageal cancer	6.69e-06	4.89e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP19A1—esophageal cancer	6.65e-06	4.87e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ABCB1—esophageal cancer	6.65e-06	4.86e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	6.52e-06	4.77e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.51e-06	4.76e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.45e-06	4.72e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EP300—esophageal cancer	6.4e-06	4.68e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EP300—esophageal cancer	6.38e-06	4.67e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—esophageal cancer	6.21e-06	4.55e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—EP300—esophageal cancer	6.19e-06	4.53e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CREBBP—esophageal cancer	6.15e-06	4.5e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GNG7—esophageal cancer	6.14e-06	4.49e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—esophageal cancer	6.08e-06	4.44e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HMOX1—esophageal cancer	6.07e-06	4.44e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—esophageal cancer	5.92e-06	4.33e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1A—esophageal cancer	5.88e-06	4.3e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—esophageal cancer	5.81e-06	4.25e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.75e-06	4.21e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—esophageal cancer	5.62e-06	4.11e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EP300—esophageal cancer	5.59e-06	4.09e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—esophageal cancer	5.58e-06	4.08e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—esophageal cancer	5.56e-06	4.07e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—esophageal cancer	5.52e-06	4.04e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—esophageal cancer	5.51e-06	4.03e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.47e-06	4e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—esophageal cancer	5.45e-06	3.99e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—esophageal cancer	5.44e-06	3.98e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.41e-06	3.96e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—esophageal cancer	5.34e-06	3.91e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—esophageal cancer	5.15e-06	3.77e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—esophageal cancer	5.13e-06	3.76e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.13e-06	3.75e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ENO1—esophageal cancer	5.13e-06	3.75e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.06e-06	3.7e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PSME2—esophageal cancer	5.05e-06	3.7e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PSME1—esophageal cancer	5.05e-06	3.7e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.03e-06	3.68e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1A—esophageal cancer	4.97e-06	3.63e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—esophageal cancer	4.87e-06	3.57e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—esophageal cancer	4.77e-06	3.49e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—esophageal cancer	4.73e-06	3.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EP300—esophageal cancer	4.73e-06	3.46e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—esophageal cancer	4.72e-06	3.45e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—esophageal cancer	4.58e-06	3.35e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—esophageal cancer	4.58e-06	3.35e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—esophageal cancer	4.56e-06	3.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—esophageal cancer	4.55e-06	3.33e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CREBBP—esophageal cancer	4.47e-06	3.27e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CREBBP—esophageal cancer	4.44e-06	3.25e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1A—esophageal cancer	4.4e-06	3.22e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.36e-06	3.19e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EP300—esophageal cancer	4.19e-06	3.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—esophageal cancer	4.14e-06	3.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—esophageal cancer	4.12e-06	3.01e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.1e-06	3e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—esophageal cancer	4.03e-06	2.95e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—esophageal cancer	4e-06	2.93e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—esophageal cancer	4e-06	2.93e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—esophageal cancer	3.98e-06	2.91e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CREBBP—esophageal cancer	3.89e-06	2.85e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.74e-06	2.74e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—esophageal cancer	3.66e-06	2.68e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—esophageal cancer	3.65e-06	2.67e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—esophageal cancer	3.64e-06	2.66e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.59e-06	2.63e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—esophageal cancer	3.57e-06	2.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—esophageal cancer	3.5e-06	2.56e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—esophageal cancer	3.49e-06	2.55e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—esophageal cancer	3.38e-06	2.47e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—esophageal cancer	3.19e-06	2.33e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—esophageal cancer	3.1e-06	2.27e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—EP300—esophageal cancer	3.04e-06	2.23e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—EP300—esophageal cancer	3.03e-06	2.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—esophageal cancer	3e-06	2.19e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—EP300—esophageal cancer	2.65e-06	1.94e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.4e-06	1.75e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.25e-06	1.65e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—esophageal cancer	2.24e-06	1.64e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—esophageal cancer	2.15e-06	1.57e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.96e-06	1.44e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.96e-06	1.44e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—EP300—esophageal cancer	1.63e-06	1.2e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.21e-06	8.84e-06	CbGpPWpGaD
